Inventions Available for Licensing

For more information, please contact Ann Smith Assistant Vice President of Research and Sponsored Programs; Xavier University of Louisiana.


Inventor: Dr. Tarun K. Mandal

Status: US Patent Application no. 11/591,028 (Publication no. 20080099938 A1)
PCT Application no. PCT/US2007/022514

Description: Microencapsulation of water soluble compounds

Abstract: The invention entails a microencapsulation technique that allows for the efficient manufacturing of acid-salt based medications for sustained release. The method employs a water-oil emulsion containing a biodegradable copolymer, in this case PLGA, whose degradation is easily adjusted to set the appropriate release rate. The experimental model, Buprenorphine HC1, has shown a constant long-term release up to 45 days in-vitro when produced using this method.

Applications: This method of microencapsulation is applicable to any acid-salt. It should be utilized for drugs needing to be administered at a constant rate for an extended period of time. This method advantageously provides a predictable and consistent drug delivery regimen, reducing potential adverse reactions due to initial drug bursts. Although the primary acid salt used during the development of this method was Buprenorphine HC1, other acid-salts are expected to show similar results. From the nature of this method, treatments for the following conditions appear especially relevant: chronic pain and addiction.

Advantages: 1) Prevent active compound loss during the microencapsulation of highly water soluble compounds
2) Reduce initial “burst effect” during release
3) Preparation of long acting sustained release formulation


Inventor: Dr. Tarun K. Mandal

Status: US Patent Application no. 11/739,219; PCT Application no. PCT/IB2008/051529

Description: Automated Control Release Multiple Layer Coating

Abstract: This invention is comprised of a computer controlled, dynamic coating system that is connected to a commercially available fluidized bed. The computerized coating system is currently designed to control flow rate, total volume of solution per cycle, pause time, and the number of total cycles, though other features may be added. Once a delivery program is set, manual oversight is unnecessary, allowing for a hands-off production cycle. This process allows for multiple layers to be formed without changing out solutions in the machine, so as to produce a layer on the tablet that is solely drug or solely coating effectively, a feature that is novel and not commercially available for lab scale multi-layer coating today.

Applications: (1) Automated multiple layer coating for controlled release formulation.
(2) Automated multiple layer coating for agriculture industry.
(3) Automated multiple layer coating with two or more incompatible coating materials.

Advantages: This technology will overall decrease the cost of production for fluid bed owners by decreasing the number of inconsistent batches and by making it more time efficient for relevant applications. It will also decrease the need for manual oversight.

This invention is specifically designed for a laboratory scale fluidized bed system and will be most pertinent for research and development applications. It is envisioned feasible for fluid bed manufactures to offer the presented technology as an add-on product that is specifically designed to use with their system. This will give consumers the opportunity to buy this technology as an additional product suiting specific multi-layer coating needs. Manufacturers may also choose to package this technology in conglomeration with their fluid bed system and sell it as a whole. Although this product is designed for pharmaceutical applications, it may also be used in the fields of probiotics, dietary supplements, and for agricultural applications like fertilizers and insecticides.


Inventor: Dr. Tien L. Huang, et al.

Status: US Patent Application no. 60/873,344; (Pub. No. US 2008/0139534 A1) PCT Application no. PCT/US2007/086773 (International Pub. no. 008/070831 A3)

Description: Bisbenzamidines and bisbenzamidoximes for the treatment of Human African Trypanosomiasis

Abstract: Disclosed are bisbenzamidine and bisbenzamidoxime compounds useful for treatment of trypanosomiasis. The compounds disclosed are useful for treating mammals infected with parasitic hemoflagellates, in particular Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense.

Applications: Treatment of HAT

Advantages: The drug candidates of the invention are characterized by high efficacy against drug-sensitive and drug-resistant strains of trypanosoma brucei, low toxicity and good oral bioavailability.


Inventor: Dr. Partha Bhattacharjee, et. al.

Status: Pending

Description: A Method of Inhibiting Angiogenesis

Abstract: Angiogenesis, the formation of new blood vessels from pre-existing capillaries is a complex process involving endothelial cell proliferation, migration and new tube formation. Tumor growth and spread of tumor cells require angiogenesis. Therefore, therapeutic strategy targeting angiogenesis is considered important for cancer and other pathological angiogenesis treatment.

Vascular endothelial growth factor (VEGF)-mediated angiogenesis is an important signaling pathway that regulates multiple downstream intracellular signaling networks. Blocking VEGF-mediated angiogenic signaling is considered best among many pre-clinical approaches against tumor, anti-cancer and ocular angiogenesis treatment.

The present invention claims that a novel dimer peptide mimetic of human apolipoprotein E (apoEdp) can effectively block VEGF-induced angiogenesis in rabbit eye model and mouse xenograft tumor model in vivo. We also claim that apoEdp inhibits VEGF-induced HUVEC migration, inhibition, proliferation and tube formation in vitro. We determined that apoEdp inhibits VEGF-mediated angiogenesis by blocking c-SRC, e-NOS, Akt, FAK and Erk1/2 signaling pathways.


1) Blocking tumor angiogenesis.

2) Blocking ocular angiogenesis

Advantages: Tumor growth is dependent on angiogenesis and angiogenesis inhibition is a novel therapeutic strategy against controlling tumors. We claim that apoEpd peptide significantly inhibits tumor growth in nude mice with aggressive breast cancer cells MDA-MB-231. The apoEdp inhibits the growth of MDA-MB-231 in vitro. ApoEdp also inhibited HUVEC cell migration, proliferation, invasion and tube formation. These results suggest that apoEdp inhibits tumor growth in vivo directly through inhibiting tumor cell proliferation and through inhibiting tumor angiogenesis. Reports suggest that one of the widely used antitumor drugs for clinic treatment, Cisplatin, can make tumor-bearing mice lose body weight and cause a lower survival rate. In our experiments, we found that apoEdp treated mice did not show any body loss and their survival rate was much higher than that of the control groups, suggesting that apoEdp has lower side effects and little toxicity compared with traditional antitumor drugs.